

4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Keynote Speakers

New Catalytic Approaches for Simplifying Complex Molecule Synthesis (KL01)



Prof. Darren J. DIXON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

The Discovery of PAXLOVID (KL02)



Dr Dafydd OWEN
(PFIZER, Cambridge, United States)

Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03)



Prof. M. Christina WHITE
(UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States)

From Underground to Mainstream: Neglected and Novel, Emerging Functional Groups for Drug Discovery

Boron Based Heterocycles and their Application in Drug Discovery (PL05)



Prof. Bhaskar DAS
(LONG ISLAND UNIVERSITY, Brooklyn, United States)

“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery (PL06)



Dr Yoshihiro ISHIHARA
(VIVIDION THERAPEUTICS, San Diego, United States)

Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07)



Prof. Tracey PIRALI
(UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy)

New Functional Groups for Synthetic and Discovery Chemistry (PL08)



Prof. Michael WILLIS
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Human Dose Prediction in the Discovery Space

Early Human Dose Predictions in Lead Optimization (PL13)



Dr Johan BYLUND
(CTC CLINICAL TRIAL CONSULTANTS AB, Uppsala, Sweden)

4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16)



Dr Nicola COLCLOUGH
(ASTRAZENECA, Cambridge, United Kingdom)

Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14)



Dr Gregori GEREBTZOFF
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15)



Dr Andres OLIVARES
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Radical Intermediates in Complex Molecule Synthesis

Recent Adventures in Catalysis and Beyond (PL22)



Prof. Bill MORANDI
(ETH ZÜRICH, Zürich, Switzerland)

Alkenes as Flexible Platforms for Asymmetric Transformations (PL23)



Prof. Cristina NEVADO
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21)



Prof. Bart PIEBER
(INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (ISTA), Klosterneuburg, Austria)

(SOPLVIAS AG (WAS FUJIFILM))

Attempts to Deliver on the Promise of Natural Product Synthesis (PL24)



Prof. Ryan SHENVI
(SCRIPPS RESEARCH, La Jolla, United States)

Cryo-EM: Applications for Structure-Based Drug Discovery

Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25)



Prof. Kazuhiro ABE
(NAGOYA UNIVERSITY, Nagoya, Japan)

4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26)



Dr Rebecca EBENHOCH
(BOEHRINGER INGELHEIM, Biberach, Germany)

Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27)



Prof. Jonathan F. FAY
(UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, Chapel Hill, United States)

Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28)



Dr Harini KRISHNAMURTHY
(MERCK, SHARP & DOHME, Blue Bell, United States)

Recent Developments in Synthetic Methodologies and their Impact

Organic Reactions in Aqueous Medium enabled by Surfactants (PL01)



Dr Niginia BORLINGHAUS
(UNIVERSITY OF KONSTANZ, Konstanz, Germany)

Reagents and Catalysts with Translational Potential (PL02)



Dr Josep CORNELLA COSTA
(MAX PLANCK INSTITUTE FOR COAL RESEARCH, Mülheim an der Ruhr, Germany)

From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03)



Prof. Timothy NOËL
(UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands)

Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04)



Prof. Francesca PARADISI
(UNIVERSITY OF BERN, Bern, Switzerland)

Antiviral Drug Discovery

Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17)



Dr Alexander BIRKMANN
(AICURIS ANTI-INFECTIVE CURES AG, Wuppertal, Germany)

Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18)

4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Dr Dimitar GOTCHEV
(ARBUTUS BIOPHARMA, Doylestown, United States)

Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20)



Dr Rao KALLA
(GILEAD SCIENCES, Foster City, United States)

Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19)



Prof. Priscilla YANG
(STANFORD UNIVERSITY, Stanford, United States)

Latest Advances and Approaches in Bioconjugation Drug Discovery

Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10)



Prof. Christian HACKENBERGER
(FMP BERLIN, Berlin, Germany)

Bicyclic Peptides as a Novel Therapeutic Modality (PL09)



Dr Philip MURRAY
(BICYCLE THERAPEUTICS, Cambridge, United Kingdom)

(SOPLVIAS AG (WAS FUJIFILM))

Creating Next-Generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11)



Dr Vijaya R. PATTABIRAMAN
(BRIGHT PEAK THERAPEUTICS, Basel, Switzerland)

Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12)



Dr Alain WAGNER
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

Drug Discovery Tales I

Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05)



Prof. Maria Paola COSTI
(UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy)

4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04)



Dr Luca GOBBI
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02)



Dr Isabelle KRIMM
(CLB, Lyon, France)

Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03)



Dr Christian KUTTRUFF
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

NLRP3 Inhibitors for Neurodegenerative Disorders (OC01)



Dr Oscar MAMMOLITI
(JANSSEN RESEARCH & DEVELOPMENT, Beerse, Belgium)

Drug Discovery Tales II

Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06)



Dr Michael G. HAHN
(BAYER AG PHARMACEUTICALS, Wuppertal, Germany)

Discovery of LY3154885, a Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (OC09)



Dr Erik HEMBRE
(ELI LILLY AND COMPANY, Indianapolis, United States)

Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07)



Dr Ana MINATTI
(AMGEN INC, Copenhagen, Denmark)

Novel Approaches to Molecular Glue Discovery: Design of Clinical Candidate NVP-DKY709 an IKZF2 Degradar by Re-Programming of CRBN Selectivity and Screening for Cooperativity Using DNA Encoded Libraries (OC8)



Dr Frédéric ZECRI
(NOVARTIS, Cambridge, United States)